Crucell N.V. and Novartis Vaccines and Diagnostics, Inc. have extended a non-exclusive research license agreement for PER.C6. The agreement allows Novartis to use Crucell’s cell technology in manufacturing alphavirus vectors for its vaccine research programs. Financial details were not disclosed. The PER.C6 technology is a cell line for the development and large-scale manufacture of biopharma products including vaccines....